{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:05:45Z","timestamp":1791655545571,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T00:00:00Z","timestamp":1544227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00280-018-3738-x","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T02:57:55Z","timestamp":1544237875000},"page":"411-417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase II trial of the effect of perindopril on hand\u2013foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC"],"prefix":"10.1007","volume":"83","author":[{"given":"Barbara L.","family":"Melosky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard John","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine Marie","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian K.","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Yi","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon A.","family":"Vandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel John","family":"Renouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,8]]},"reference":[{"key":"3738_CR1","unstructured":"Canadian Cancer Statistics (2018) \n                    http:\/\/www.cancer.ca\/~\/media\/cancer.ca\/CW\/cancerinformation\/cancer101\/Canadian cancer statistics\/Canadian-Cancer-Statistics-2018-EN.pdf?la=en\n                    \n                  . Canadian Cancer Society, 2018. Accessed 18 June 2018"},{"key":"3738_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/bmj.306.6880.752","volume":"306","author":"W Scheithauer","year":"1993","unstructured":"Scheithauer W, Rosen H, Kornek GV et al (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752\u2013755","journal-title":"BMJ"},{"key":"3738_CR3","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ et al (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317:2392\u20132401","journal-title":"JAMA"},{"key":"3738_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312","journal-title":"Lancet"},{"key":"3738_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16:619\u2013629","journal-title":"Lancet Oncol"},{"key":"3738_CR6","unstructured":"STIVARGA\u00ae PRODUCT MONOGRAPH (2018) \n                    https:\/\/omr.bayer.ca\/omr\/online\/stivarga-pm-en.pdf\n                    \n                  . Bayer Inc. Accessed 18 June 2018"},{"key":"3738_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1096\/fj.03-0271fje","volume":"18","author":"R Erber","year":"2004","unstructured":"Erber R, Thurnher A, Katsen AD et al (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338\u2013340","journal-title":"FASEB J"},{"key":"3738_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","volume":"6","author":"C Robert","year":"2005","unstructured":"Robert C, Soria JC, Spatz A et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491\u2013500","journal-title":"Lancet Oncol"},{"key":"3738_CR9","unstructured":"Perindopril Product Monograph (2017) \n                    https:\/\/www.servier.ca\/sites\/default\/files\/webform\/products\/PMCOVERSYLPLUSEnglish13Oct2017.pdf?ts=1511532317\n                    \n                  . Servier Canada Inc., Accessed 18 June 2018"},{"key":"3738_CR10","first-page":"17","volume":"34","author":"S Taddei","year":"2012","unstructured":"Taddei S (2012) New evidence for endothelial protection. Medicographica 34:17\u201324","journal-title":"Medicographica"},{"key":"3738_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0735-1097(99)00537-9","volume":"35","author":"TJ Anderson","year":"2000","unstructured":"Anderson TJ, Elstein E, Haber H et al (2000) Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 35:60\u201366","journal-title":"J Am Coll Cardiol"},{"key":"3738_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cardiores.2006.10.021","volume":"73","author":"C Ceconi","year":"2007","unstructured":"Ceconi C, Fox KM, Remme WJ et al (2007) ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: Pertinent. Cardiovasc Res 73:237\u2013246","journal-title":"Cardiovasc Res"},{"key":"3738_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2007.07.061","volume":"577","author":"C Ceconi","year":"2007","unstructured":"Ceconi C, Francolini G, Olivares A et al (2007) Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 577:1\u20136","journal-title":"Eur J Pharmacol"},{"key":"3738_CR14","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/hy0202.103417","volume":"39","author":"JL Zhuo","year":"2002","unstructured":"Zhuo JL, Mendelsohn FA, Ohishi M (2002) Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 39:634\u2013638","journal-title":"Hypertension"},{"key":"3738_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2018.36.4_suppl.611","volume":"36","author":"TS Bekaii-Saab","year":"2018","unstructured":"Bekaii-Saab TS, Ou F-S, Anderson DM et al (2018) Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC): An ACCRU Network study. J Clin Oncol 36:611\u2013611","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3738-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3738-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3738-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,8]],"date-time":"2019-12-08T00:19:25Z","timestamp":1575764365000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3738-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,8]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3738"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3738-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,8]]},"assertion":[{"value":"19 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Barbara L. Melosky: Advisory Board\/honorarium: Bayer, Pfizer, Astra Zeneca, Boerhinger Ingleheim, Roche. Research funding: Bayer. Howard John Lim: honoraria from Bayer. Janine Davies: honoraria from Bayer. Sharlene Gill: no relevant disclosures. Christian K. Kollmannsberger: no relevant disclosures. Maria Ho: no relevant disclosures. Solomon A. Vandt: no relevant disclosures. Daniel John Renouf: Advisory board\/honorarium: Celgene; Shire; Bayer. Research funding: Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}